HomePipeline
6 molecules
1 receptor family
PNB Vesper's pipeline comprises six patented new chemical entities (NCEs), all derived from its proprietary cholecystokinin (CCK) receptor platform. Two molecules are currently in clinical development with 6 indications, while four have successfully completed preclinical studies and ready for Regulatory IND studies
- New chemical entities
- 6
- In clinical trials
- 2
- Molecule–indication programmes
- 14
- Therapeutic areas
- 4
Programme highlights.
Where PNB Vesper's main programmes stand today.
-
- Phase II clinical trials completed for both indications with significant results.
- Phase III clinical trial application for Ulcerative Colitis submitted to DCGI.
-
- Phase II clinical trial application submitted to DCGI; provisional approval received, awaiting final approval.
- Novel mechanism of action with disease-modifying effects. First in class.
-
- Collaboration with the US Government's NIH / NIDA, covering Cocaine Addiction, Opioid Addiction and Substance Use Disorders.
- Cocaine Addiction studies completed by the National Institute on Drug Abuse, USA, with significant results.
- Confirmatory opioid efficacy studies ongoing with NIH / NIDA.
- Advancing towards IND-enabling and clinical trial studies in the US, in association with the US Government agency.
-
- Phase I/IIa clinical trial approved by DCGI.
- Trial ongoing with Tata Memorial Hospital, Mumbai.
-
- Phase I/IIa clinical trial approved by DCGI.
- Clinical trial ongoing with Tata Memorial Hospital, Mumbai.
-
- Phase II clinical trials completed with significant results.
- DCGI approval received to conduct a Phase III clinical trial.
- Significant findings in patients with severe COVID-19 with Lung Inflammation.
- Powerful anti-inflammatory and immunomodulatory mechanism identified.
- Trial paused following the emergence of the Omicron variant.
-
- Overall six new chemical entities (NCEs) targeting 14 serious and unmet medical indications.
- Additional programmes targeting Brain Cancer, Lung Cancer, Liver Cancer, Triple-Resistant Breast Cancer, Stomach Cancer and Pancreatitis are ready to move on to IND studies.
Stage of development
Every Molecules Grouped By Thelaputic Areas, with the biological action and stage for each indication
Immune & inflammation3 programmes
-
PNB-001
COVID-19 Lung InflammationCCK ligand, lymphokine
- Molecule
- PNB-001
- Indication
- COVID-19 Lung Inflammation
- Biological action
- CCK ligand, lymphokine
- Status
- Phase 3 approved · currently stopped because of the Omicron variant
-
PNB-001
Ulcerative ColitisCCK ligand, lymphokine, T-cell activation
- Molecule
- PNB-001
- Indication
- Ulcerative Colitis
- Biological action
- CCK ligand, lymphokine, T-cell activation
- Status
- Phase 3 submission
-
PNB-001
Crohn's DiseaseCCK ligand, lymphokine, T-cell activation
- Molecule
- PNB-001
- Indication
- Crohn's Disease
- Biological action
- CCK ligand, lymphokine, T-cell activation
- Status
- Phase 2 completed
Oncology5 programmes
-
PNB-028
Pancreatic CancerCCK inhibition via the CCK-C receptor
- Molecule
- PNB-028
- Indication
- Pancreatic Cancer
- Biological action
- CCK inhibition via the CCK-C receptor
- Status
- Phase 1/2a ongoing
-
PNB-028
Colon CancerCCK inhibition via the CCK-C receptor
- Molecule
- PNB-028
- Indication
- Colon Cancer
- Biological action
- CCK inhibition via the CCK-C receptor
- Status
- Phase 1/2a ongoing
-
PNB-101
Lung CancerCCK-B pathway inhibition
- Molecule
- PNB-101
- Indication
- Lung Cancer
- Biological action
- CCK-B pathway inhibition
- Status
- IND ready
-
PNB-101
Liver CancerCCK-B pathway inhibition
- Molecule
- PNB-101
- Indication
- Liver Cancer
- Biological action
- CCK-B pathway inhibition
- Status
- IND ready
-
PNB-291
Brain CancerPan-CCK blocker
- Molecule
- PNB-291
- Indication
- Brain Cancer
- Biological action
- Pan-CCK blocker
- Status
- IND ready
CNS & addiction3 programmes
-
- Molecule
- PNB-001
- Indication
- Dementia
- Biological action
- CCK-mediated release of acetylcholine (ACh)
- Status
- Phase 2 ready
-
PNB-081
Opiate ManagementCCK-A antagonist
- Molecule
- PNB-081
- Indication
- Opiate Management
- Biological action
- CCK-A antagonist
- Status
- IND ready
-
PNB-091
Cocaine AddictionPan-CCK blocker
- Molecule
- PNB-091
- Indication
- Cocaine Addiction
- Biological action
- Pan-CCK blocker
- Status
- IND ready
Metabolic Diseases3 programmes
-
PNB-001
Type 2 DiabetesCCK-mediated blood glucose reduction; restoration of pancreatic cells
- Molecule
- PNB-001
- Indication
- Type 2 Diabetes
- Biological action
- CCK-mediated blood glucose reduction; restoration of pancreatic cells
- Status
- Phase 2 submission
-
PNB-028
PancreatitisInhibition of pancreatic enzymes
- Molecule
- PNB-028
- Indication
- Pancreatitis
- Biological action
- Inhibition of pancreatic enzymes
- Status
- Phase 1 ready
-
- Molecule
- PNB-081
- Indication
- Obesity
- Biological action
- CCK-mediated reduction of food intake
- Status
- IND ready
Molecules and indications
Each molecule acts on CCK receptors in a different way, so several reach more than one disease.
Select a molecule to isolate its indications.
All 14 molecule–indication links are shown.
Immune & inflammation
CNS & addiction
Metabolic Diseases
Molecule profiles
Select a molecule to see the indications it is being developed for. Each indication opens its study: target, preclinical findings, development and clinical status.
5indications
Front-runner
Clinical · Phase 1 and Phase 2 completed
3indications
Second clinical molecule
Clinical · Phase 1/2a ongoing
PNB-0015 indications
Immune & inflammation
Metabolic Diseases
CNS & addiction
PNB-0283 indications
Metabolic Diseases
PNB-0812 indications
Metabolic Diseases
CNS & addiction
PNB-1012 indications
PNB-2911 indication
Oncology
PNB-0911 indication
CNS & addiction
Interested in a programme?
PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.
